Physician profile
Carlos A Riveros
NPI 1568652048
$5,070.07
in general payments reported to CMS, 2019-2025
40 companies · $598 in 2025
The $598 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $781 · 2021: $1,211 · 2022: $733 · 2023: $625 · 2024: $430 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.07 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.12 | 2020-2025 | Ubrelvy |
| Novo Nordisk INC | $475.17 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $459.05 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.11 | 2019-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $352.58 | 2020-2025 | Farxiga |
| Pfizer INC. | $244.67 | 2019-2025 | |
| Amgen INC. | $227.92 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Biotissue Holdings INC. | $190.39 | 2025 | |
| Novartis Pharmaceuticals Corporation | $168.22 | 2021-2024 | |
| Radius Health, INC. | $167.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.58 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $147.78 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $144.70 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $130.59 | 2024-2025 | Veozah |
| Amarin Pharma, INC. | $129.49 | 2020-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $119.53 | 2023-2025 | Shingrix, Arexvy |
| Ironwood Pharmaceuticals, INC | $116.54 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.76 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $93.03 | 2022-2024 | Quviviq |
| Smith+Nephew, INC. | $91.26 | 2021-2024 | Stravix, Oasis, Grafix Pl |
| Lilly USA, LLC | $89.05 | 2019-2024 | Mounjaro |
| Abbott Laboratories | $82.05 | 2022-2023 | Proclaim, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $43.47 | 2022-2023 | Seglentis |
| Access Pro Medical, LLC | $43.01 | 2025 | Matriderm |
| Nevro Corp. | $41.74 | 2022 | |
| Ibsa Pharma INC. | $36.56 | 2023 | Tirosint, Licart |
| E.R. Squibb & Sons, L.L.C. | $33.61 | 2019-2025 | Camzyos |
| Currax Pharmaceuticals LLC | $28.66 | 2020-2021 | |
| Integra Lifesciences Corporation | $25.71 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Djo, LLC | $24.49 | 2019 | |
| Horizon Therapeutics Plc | $20.66 | 2023 | Krystexxa |
| Evoke Pharma, INC. | $20.13 | 2020 | |
| Insightec,INC | $19.89 | 2025 | Exablate |
| Nestle Healthcare Nutrition INC. | $19.81 | 2021 | |
| Genentech USA, INC. | $18.98 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.57 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.05 | 2022 | |
| Tolmar, INC. | $14.70 | 2025 | Eligard, Jatenzo |
| Gilead Sciences, INC. | $14.27 | 2020 | |
| Bioventus LLC | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Riveros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.